Dermatology · Flint, MI
NPI
1205222171
Since 2015
Specialty
Dermatology
Code 207N00000X
Group practices
4
Medicare group memberships
Hospitals
1
Hospital affiliations
5097 Miller Rd Ste 1
Flint, MI, 48507
Phone (833) 322-3376
Groups this clinician bills Medicare through
Medicare paid, 2024
$303K
6,316 services
Medicare patients, 2024
339
Average age 70
Drug cost, 2024
$2.4M
3,474 prescriptions
Company payments, 2025
$80K
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wasim Nasir was code 17003 (destruction skin lesion), 710 times for 99 patients. In total Wasim Nasir billed 6,316 services in 57 codes, and Medicare paid $303K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 710 | 99 | $4.62 | $3,284 |
| 99214 Office E&M - Established | Office | 484 | 212 | $85.79 | $42K |
| 99213 Office E&M - Established | Office | 302 | 172 | $65.52 | $20K |
| 17110 Destruction Skin Lesion | Office | 264 | 150 | $72.99 | $19K |
| 17000 Destruction Skin Lesion | Office | 238 | 123 | $31.74 | $7,553 |
| 99204 Office E&M - New | Office | 184 | 184 | $106.75 | $20K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 132 | 37 | $0.75 | $99.01 |
| 11102 Skin Biopsy | Office | 92 | 82 | $56.11 | $5,162 |
| 11104 Skin Biopsy | Office | 63 | 58 | $85.92 | $5,413 |
| 17311 Mohs Surgery | Office | 60 | 54 | $493.94 | $30K |
| 11900 Skin | Office | 58 | 34 | $38.19 | $2,215 |
| 96372 Injection Administration | Office | 46 | 18 | $9.74 | $448 |
| 99203 Office E&M - New | Office | 40 | 40 | $79.63 | $3,185 |
| 17312 Mohs Surgery | Office | 35 | 29 | $295.25 | $10K |
| 13132 Wound Repair - All Levels | Office | 32 | 28 | $196.83 | $6,299 |
By year: 2022 $59K for 1,020 services; 2023 $123K for 2,291 services; 2024 $303K for 6,316 services.
Medicare prescription drug claims, 2024
In 2024, the drug Wasim Nasir prescribed most often to Medicare patients was Ketoconazole, with 632 prescriptions and refills. In total Wasim Nasir wrote 3,474 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 632 | 686 | 297 | $10K |
| Clobetasol Propionate Generic | 496 | 509 | 276 | $12K |
| Triamcinolone Acetonide Generic | 369 | 428 | 277 | $5,370 |
| Hydrocortisone Generic | 328 | 332 | 215 | $1,747 |
| Tacrolimus Generic | 192 | 213 | 122 | $21K |
| Doxycycline Hyclate Generic | 149 | 149 | 99 | $2,850 |
| Dupixent Pen Dupilumab | 144 | 148 | 22 | $556K |
| Clindamycin Phosphate Generic | 119 | 124 | 57 | $3,763 |
| Mupirocin Generic | 86 | 86 | 76 | $644 |
| Metronidazole Generic | 73 | 77 | 37 | $2,709 |
| Pimecrolimus Generic | 59 | 65 | 38 | $13K |
| Cosentyx Unoready Pen Secukinumab | 58 | 58 | 17 | $679K |
| Hydroxyzine Hcl Generic | 58 | 63 | 27 | $571 |
| Tretinoin Generic | 56 | 63 | 28 | $2,261 |
| Spironolactone Generic | 55 | 72 | 19 | $645 |
Brand drugs: 482 claims; generic drugs: 2,992 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wasim Nasir $80K ($80K in general payments such as food, travel and fees) from 34 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $51K.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 84 | $51K |
| Incyte Corporation INCY | 30 | $8,610 |
| Pfizer Inc. PFE | 19 | $5,508 |
| Eli Lilly and Company LLY | 4 | $5,390 |
| Genzyme Corporation SNY | 24 | $4,844 |
| Abbvie Inc. ABBV | 48 | $673 |
| Lilly USA, LLC LLY | 14 | $406 |
| Janssen Biotech, Inc. JNJ | 15 | $374 |
| UCB, Inc. UCB.BR | 16 | $369 |
| Amgen Inc. AMGN | 12 | $357 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.